10 Best High Dividend Stocks To Invest In 2014

The Intelligent REIT Investor's Brad Thomas discusses his outlook for real estate and the new class of data REITs.

SPEAKER:  Hi, I'm talking with Brad Thomas today about REITs.  Thank you for joining me, Brad. 

BRAD THOMAS:  Oh, glad to be here, thanks so much. 

SPEAKER:  You're welcome.  You know, we talked a couple of months ago and you were saying to me that there were a couple of things that investors really need to think about when they're investing in REITs, and one was what is the dividend yield, obviously, and second is the safety of that dividend.  So can you expand a little bit on that? 

BRAD THOMAS:  Sure.  Well, you know, REITs today are very attractive for investors because investors are looking for dividends and dividend safety.  You must remember that REITs are unlike any other public company in that they pay out dividends, forced dividends, and what I mean by that is by law, which is a law created in 1960 in the Eisenhower administration, so this is a law that was created over five decades ago, just point that out, that REITs are required to pay out 90% of their taxable income in the form of dividends, so that's created a very sustainable model for investors today.  That's what's attracted investors to this real estate secured industry because of the sustainability of the dividend model.  So we're seeing a lot of high dividends today, again because companies are forced to pay out at least 90%.  In most cases they pay out almost 100% of their taxable income in the form of dividends. 

Top 10 Valued Companies To Buy Right Now: Compugen Ltd.(CGEN)

Compugen Ltd. operates as a drug and diagnostic discovery company based on computer-based discovery capabilities to predict and select novel product candidates. Through in silico prediction and selection, the resulting novel molecules are synthesized and validated utilizing traditional in vitro and in vivo experimental procedures. The company provides these validated product candidates to pharmaceutical, biotech, and diagnostic companies under licensing and other commercialization arrangements. Its research and discovery efforts are focused primarily on therapeutic proteins and peptides, and monoclonal antibodies, and primarily in the fields of immunology and oncology. Its therapeutic peptide and protein related platforms include Protein Family Members Discovery Platform, Protein-Protein Interaction Blockers, GPCR Therapeutic Peptide Ligands, Disease-Associated Conformation Blockers, Intracellular Drug Delivery, Viral Peptides, and Splice Variant based Therapeutic Proteins . The company?s monoclonal antibody related platforms comprise Monoclonal Antibody Targets. Its other therapeutic and diagnostic platforms consist of Nucleic-Acid Disease Markers, Protein Disease Markers, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, and New Indications. Its therapeutic peptide and protein product candidates comprise CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-25017, a novel peptide antagonist of the Angiopoietin/Tie-2 pathway; CGEN-855, a peptide agonist of the FPRL1 GPCR receptor; CGEN-856 and CGEN-857, which are MAS GPCR peptide agonists; CGEN-25007, an antagonist of the gp96 protein; and CGEN-25009, a peptide of the LGR7 receptor. The company also offers monoclonal antibody target product candidates, including CGEN-671, a drug for multiple epithelial tumors; CGEN-928, a drug for multiple myeloma; and CGEN-15001T, a novel B7/CD28 family member. Compugen Ltd. was founded in 1993 and is based in Te l Aviv, Israel.

Advisors' Opinion:

• [By Sean Williams]

  On Monday, small-cap biotechnology company Compugen (NASDAQ: CGEN  ) gave investors something to cheer about when it announced a collaboration and licensing agreement with Bayer for two of its antibody-based immunotherapies. The deal could be worth as much as $540 million for Compugen and gives the company $10 million upfront, as well as the potential for $30 million more in milestone payments during preclinical trials. The two companies will co-develop these drugs, with Bayer getting worldwide rights upon commercialization (though Compugen would still receive a mid- to high-single-digit royalty). This is great news for Compugen, as it solves the problem of seeking out a partner later, helps reduce its clinical testing costs, and staves off the need to dilute shareholders with a secondary offering to raise cash. Shares added 44% this week.

• [By Lisa Levin]

  Compugen (NASDAQ: CGEN) climbed 3.54% to $11.86 after Jefferies initiated coverage on the stock with a Buy rating and a $17.00 price target.

  Posted-In: market moversNews Intraday Update Markets Movers

10 Best High Dividend Stocks To Invest In 2014: Pharma-Bio Serv Inc (PBSV.PK)

Pharma-Bio Serv, Inc.( Pharma-Bio), incorporated on June 8, 2006, is a compliance and technology transfer services consulting firm with a laboratory testing facility, servicing the Puerto Rico, United States and Europe markets. The Company is engaged in providing technical compliance consulting service, and microbiological and chemical laboratory testing services primarily to the pharmaceutical, chemical, medical device and biotechnology industries. The Company�� operating segments include Puerto Rico technical compliance consulting, United States technical compliance consulting, Ireland technical compliance consulting and a Puerto Rico microbiological and chemical laboratory testing division (Lab). These segments provide services primarily to the pharmaceutical, chemical, medical device and biotechnology industries in their respective markets. As on April 30, 2012, the Company acquired 100% interest in its subsidiary, Pharma-IR.

The Company provides a broad range of compliance related consulting services. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It provides information technology consulting services and technical training/seminars. The Company offers services to its core industries already serviced as well as the cosmetic and food industries. The Company seeks opportunities in markets that could yield profitable margins using its professional consulting force and also provide services such as those performed by its microbiological testing laboratory facility, its information technology service division, Integratek, and its technical training division, Pharma Serv Academy.

The Company�� information technology services and consulting division based in Puerto Rico (Integratek) provides a variety of information technology services, such as Web pages and portals development, digital art design, intranets, extranets, software development including database integration, Window! s and Web applications development, software technical training and learning management systems, technology project management, and compliance consulting services, among others.

Advisors' Opinion:

• [By The Specialist]

  Normally when one of my stocks reports its earnings results after hours on a Friday, I cringe in anticipation of a bad report. Normally Friday after hours is a time slot reserved for companies who have disappointing results to deliver and wish to stay off radar. Naturally, when I got the alert on a Friday afternoon that Pharma-Bio Serv (PBSV.PK) had just reported its earnings results, I had one eye shut when opening the press release, fearing what would be inside.

10 Best High Dividend Stocks To Invest In 2014: Denny's Corporation(DENN)

Denny's Corporation, through its subsidiaries, engages in the ownership and operation of a chain of family-style restaurants. The company operates traditional American-style food restaurants under the Denny?s brand name. As of December 28, 2011, it had 1,479 franchised/licensed restaurants and 206 company-owned and operated restaurants in the United States, Canada, Costa Rica, Mexico, Honduras, Guam, Puerto Rico, and New Zealand. The company was founded in 1980 and is headquartered in Spartanburg, South Carolina.

Advisors' Opinion:

• [By Jae Jun]

  1. Turnaround Story of Denny�� (DENN): Denny�� owns and is a franchiser of family diners. The company controls about 9% of the family dining market and competes directly with IHOP which controls 11%.

10 Best High Dividend Stocks To Invest In 2014: Prothena Corporation PLC (PRTA)

Prothena Corporation PLC, incorporated on September 26, 2012, is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion. Its pipeline includes NEOD001, PRX002 and PRX003. The Company�� work in protein misfolding could result in therapies to treat several neurodegenerative diseases, including AL (primary) and AA (secondary) forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002). Its cell adhesion development activities could generate new therapies to treat inflammatory diseases and metastatic cancers (PRX003). The Company�� program, NEOD001, is in Phase 1. In addition to antibodies directed to neo-epitope targets, it is developing antibodies directed to other targets. The Company has generated antibodies against cell adhesion targets expressed on certain pathogenic Th17 immune cells and tumor cells.

The Company�� pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of disease. It is also generating additional antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro.

NEOD001 for Amyloidosis

NEOD001 is a monoclonal antibody that targets the amyloid that accumulates in both AL and AA forms of amyloidosis. The antibody was designed to not react with normal serum amyloid A and only with the aberrant cleaved form of the protein (amyloid A).

PRX002 for Parkinson�� Disease

The Company has generated antibodies targeting alpha-synuclein that may slow or reduce the neurodegeneration associated with synuclein misfolding and/or transmission. It has tested these antibodies in various cellular and animal models of synuclein-related disease. In a transgenic mouse model of Parkinson�� disease, passive immunization with 9E4, a murine ver! sion of PRX002, reduced the appearance of synuclein pathology, protected synapses and improved performance by the mice in behavioral testing. The humanized antibody product candidate PRX002 has advanced into manufacturing and preclinical testing.

PRX003 for Inflammatory Diseases and Cancers

The Company is developing PRX003, a monoclonal antibody targeting MCAM for the potential treatment of inflammatory diseases and cancers. It has generated monoclonal antibodies that block MCAM-mediated cell adhesion and have been shown to delay relapse and severity of relapse in a mouse model of multiple sclerosis known as experimental autoimmune encephalomyelitis. The Company�� antibodies are being tested in animal models of inflammatory diseases and cancers. Based on early results from these studies, it has identified a clinical candidate, PRX003. It has advanced this antibody into manufacturing and intends to advance this antibody into preclinical testing.

Advisors' Opinion:

• [By Lauren Pollock]

  Roche Holding AG(ROG.VX) has entered a pact with Prothena Corp.(PRTA) PLC to develop and commercialize a treatment the clinical-stage biotechnology firm is developing for Parkinson’s disease. In after-hours trading, Prothena’s stock rose 8.6% to $29.75 premarket.

• [By Jake L'Ecuyer]

  Equities Trading UP
  Prothena Corporation plc (NASDAQ: PRTA) shares shot up 21.60 percent to $45.19 after the company reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00.

10 Best High Dividend Stocks To Invest In 2014: Atossa Genetics Inc (ATOS)

Atossa Genetics Inc., incorporated on April 30, 2009, is a development-stage healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions. The Company�� diagnostic tests consist of medical devices cleared by the Food and Drug Administration (FDA), which can collect fluid samples from the breast milk ducts, where over 95% of breast cancers arise. During the fiscal year ended September 30, 2012, the tests that the Company offered and that are in development consist of ForeCYTE, ArgusCYTE, FullCYTE and NextCYTE. In September 2012, the Company acquired all of the assets of Acueity.

The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 73. The ArgusCYTE Breast Health Test provides information to help inform breast cancer treatment options and to help monitor potential recurrence. The FullCYTE Breast Health Test is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer. The NextCYTE Breast Cancer Test is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. MASCT, Oxy-MASCT, and its name and logo are the trademarks. ForeCYTE, FullCYTE, NextCYTE, and ArgusCYTE are its service marks.

Advisors' Opinion:

• [By Rebecca McClay]

  Atossa Genetics Inc. (Nasdaq: ATOS) shares are up about 6% in midday trading due to a cancer breakthrough it plans to showcase this weekend...

  Atossa will exhibit its ForeCYTE Breast Health Test at the 2013 Breast Cancer Symposium in San Francisco, CA, which starts Saturday.

10 Best High Dividend Stocks To Invest In 2014: Texas Roadhouse Inc.(TXRH)

Texas Roadhouse, Inc., together with its subsidiaries, operates a full-service casual dining restaurant chain. It operates restaurants under the Texas Roadhouse and Aspen Creek names. The company also provides supervisory and administrative services for other license and franchise restaurants. As of December 27, 2011, it owned and operated 294 restaurants; and franchised and licensed an additional 72 restaurants in 47 states in the United States, and Dubai, the United Arab Emirates. The company was founded in 1993 and is based in Louisville, Kentucky.

Advisors' Opinion:

• [By Seth Jayson]

  Texas Roadhouse (Nasdaq: TXRH  ) is expected to report Q2 earnings on July 29. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Texas Roadhouse's revenues will grow 10.7% and EPS will increase 3.6%.

• [By Ben Levisohn]

  Peter Saleh of Telsey Advisory Group assumes that Darden sells or spins off Red Lobster in the next three to six months. ��t that point, the activists will have failed to break the company up, and will sell the stock.��In that event, then, investors might flee to an alternative like, say, Texas Roadhouse (TXRH), which trades at 20 times forward earnings, with estimated long-term earnings growth of 13.2%, versus Darden�� 18 times earnings and 9% earnings growth. Saleh thinks Darden is worth $45, somewhat less than today�� price, given ��xecution risk in spinning out Red Lobster.��/p>

• [By Marc Bastow]

  Full service restaurant group Texas Roadhouse (TXRH) raised its quarterly dividend 25% to 15 cents per share, payable April 4 to shareholders of record as of March 19.
  TRXH Dividend Yield: 2.25%

• [By Rick Munarriz]

  Shares of Texas Roadhouse (NASDAQ: TXRH  ) opened 9% higher today after it clocked in with a strong report last night. The casual steakhouse chain is reporting comps growing 3.5% at company restaurants and 4.5% at franchised locations.

10 Best High Dividend Stocks To Invest In 2014: Puget Technologies Inc (PUGE)

PUGET TECHNOLOGIES, INC., incorporated on March 17, 2010, is a development-stage company. The Company is engaged in the distribution of luxury wool bedding sets produced in Germany. The Company�� product includes Lama Wool, Camel Wool, Cashmere Wool and Merino Wool.

The Company�� Lama Wool is consists of 50% Lama Wool hair, and 50% Merino wool hair. The Camel wool is consists of 50% Camel wool hair, and 50% Merino wool hair. The Cashmere wool is blended with Merino wool.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Inscor, Inc (OTCMKTS: IOGA), Puget Technologies Inc (OTCBB: PUGE) and PTA Holdings Inc (OTCMKTS: PTAH) have all been getting some attention lately in various investment newsletters or investor alerts. However, two of these small caps have been the subject of paid promotions while the third is getting attention largely because its in the growing marijuana or cannabis business. With that in mind, are these stocks really all that hot or not? Here is a quick reality check: